Repair & Recovery Synthetic tripeptideNot FDA-approved · research compound

KPV

Lysine-Proline-Valine · KPV Tripeptide · Lys-Pro-Val

Evidence: Preclinical / animal. Example dose: finalize with a provider. Not a fact-check stamp.

200 to 500 mcg daily – 200-500 mcg SubQ Daily or 5 days on / 2 days off

500-1000 mcg Oral Daily

Alpha-MSH C-terminal fragmentNF-kB pathway suppressorAnti-inflammatory signaling peptide

KPV is a synthetic tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte stimulating hormone (alpha-MSH). It retains the potent anti-inflammatory signaling of the parent hormone while lacking the melanogenic (skin darkening) and appetite-suppressive properties associated with the full alpha-MSH sequence. KPV exerts its anti-inflammatory effects primarily through suppression of the NF-kB signaling pathway, one of the master regulators of inflammatory gene expression. It has been studied in the context of inflammatory bowel disease, mucosal inflammation, skin inflammation, and systemic inflammatory conditions. Its small size (3 amino acids) makes it highly stable, easily absorbed, and amenable to syringe mixing with most other peptides.

Quick Start

Route

SubQ injection. Oral and topical routes also discussed.

Start low

200 to 500 mcg SubQ

Frequency

Daily or 5 days on / 2 days off

Timing

No evidence-based fed or fasted requirement

SubQ: Any time of day. Oral: Take on empty stomach for GI targeting (PepT1 transporter absorption). Wait 30 minutes before eating.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

200 to 500 mcg daily · SubQ injection. Oral and topical routes also discussed. · Daily or 5 days on / 2 days off

conservative starter

200 to 500 mcg daily

Daily or 5 days on / 2 days off

Standard

Systemic Anti-Inflammatory

200-500 mcg · SubQ · Daily

animal study · Dalmasso et al. 2008 (Gastroenterology)

C-terminal alpha-MSH fragment - anti-inflammatory without the melanocortin tanning effect. The study cited here is animal research. It shows the mechanism, not a human dose, and this amount is community practice rather than a trial result.

200-500 mcg

Daily

Standard

Oral (Gut)

500-1000 mcg · Oral · Daily

anecdotal · community

Used for GI inflammation (IBD/IBS); PepT1 transporters concentrate in the gut. Oral use is community-driven.

500-1000 mcg

Daily

Reconstitution CalculatorU-100

Vial strength

BAC water

Vials in this mix

Syringe size

Target dose

050100u

Draw to

— units

◆

I will split this dose across more than one syringe

◆

How it works

KPV suppresses the NF-kB inflammatory signaling cascade by preventing nuclear translocation of NF-kB p65 subunit, thereby reducing transcription of pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and TNF-alpha. Unlike NSAIDs which target COX enzymes or corticosteroids which broadly suppress immune function, KPV's NF-kB modulation is a more upstream and targeted anti-inflammatory mechanism. KPV also interacts with melanocortin receptors (MC1R, MC3R, MC5R) but with reduced affinity compared to full-length alpha-MSH, which explains its minimal melanogenic activity. The peptide has been shown to penetrate inflamed mucosal tissue and accumulate at sites of intestinal inflammation, making it particularly relevant for GI applications.

What to expect

Early

Days 1–7

Days 1-7: Some users report early improvements in GI comfort and reduced bloating. Anti-inflammatory signaling begins immediately but clinical effects take time.

Mid

Weeks 2–4

Weeks 2-4: Consistent improvement in gut comfort and bowel function. Skin inflammation improvements noticeable if applicable. Systemic inflammation markers may begin to improve.

Later

Weeks 4–12

Weeks 4-12: Cumulative anti-inflammatory and mucosal healing effects. Best results when combined with BPC-157 for gut healing. Inflammatory markers (CRP, ESR) may show measurable improvement.

Evidence

HumanNo published trials

AnimalModerate

In-vitroStrong

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

Evidence boundary from the checked abstract: Changes in Rt and Kd of aldosterone binding activity were observed after injection of anti-rat TNF alpha and IL-1 beta antibodies, alpha-melanocyte-stimulating hormone (alpha-MSH) and KPV peptide (Ac-D-Lys-L-Pro-D-Val).

Changes in Rt and Kd of aldosterone binding activity were observed after injection of anti-rat TNF alpha and IL-1 beta antibodies, alpha-melanocyte-stimulating hormone (alpha-MSH) and KPV peptide (Ac-D-Lys-L-Pro-D-Val).

[Changes in aldosterone binding activity of kidney cytosol after stress in rats and the regulation]. Sheng li xue bao : [Acta physiologica Sinica] · 2001 · PMID 11833422

Evidence scope. This entry supports only the exact statement quoted from the live abstract; it does not independently verify OnePin's displayed dose, route, frequency, formulation, population, or broader mechanism.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 200 to 500 mcg daily; SubQ injection. Oral and topical routes also discussed.; Daily or 5 days on / 2 days off. No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.

Primary safety claim: No primary safety text present in source JSON. No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.

The honest take

◆

IBD / Colitis treatment

Animal colitis models show significant efficacy. Mechanism (NF-kB suppression in gut mucosa) is well-characterized. Not a validated IBD treatment in humans. Promising preclinical data.

Skin anti-inflammatory

In vitro and limited in vivo data support anti-inflammatory effects on keratinocytes and dermal tissue. Topical formulations studied. Not a validated dermatological treatment.

No melanogenic activity

Confirmed. KPV retains the anti-inflammatory fragment of alpha-MSH without the melanocortin receptor activation responsible for skin darkening. This is its key advantage over MT-II for anti-inflammatory purposes.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

AOD-9604Non-overlapping (anti-inflammatory vs fat metabolism)

ARA-290Both anti-inflammatory through different pathways

LL-37KPV anti-inflammatory + LL-37 antimicrobial

SS-31Non-overlapping (inflammation vs mitochondria)

Keep separate

CJC-1295 with DACDAC maleimide reactivity concern in syringe.

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Side effects & safety

Commonly reported

Generally very well tolerated (simple tripeptide)
Minimal injection site reactions
Rare reports of mild fatigue

Less common & notes

KPV is a naturally occurring fragment of alpha-MSH with an excellent safety profile.
Unlike full-length alpha-MSH or MT-II, KPV does not cause significant melanogenesis (skin darkening) or appetite changes.
Individuals with autoimmune conditions should consult their physician as NF-kB modulation could theoretically affect immune regulation.
Long-term human safety data is not established.

Pharmacokinetics

Illustrative plasma concentration · 2.3 h

Half-life

0.5h

Peak · Tmax

0.25h

Elimination

2.5h

Bioavailability

~100%

SubQ

Duration of action

6-12 hours

NF-kB suppression persists beyond plasma clearance

Clearance

Enzymatic degradation (peptidases)

Storage. Store unreconstituted vials frozen (-20C) or refrigerated (2-8C). After reconstitution with BAC water, refrigerate at 2-8C. Stable for 28-30 days. Small tripeptide structure confers favorable stability. Protect from light.

Regulatory status

KPV is not FDA-approved for any indication. Available as a research peptide and through compounding pharmacies. WADA status is not specifically addressed. Not a scheduled or controlled substance.

Put it to work

Calculate, log & track

Open KPV straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open KPV in the app →

Go deeper

The guide & community

The complete KPV walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community